PeptideAnecdotalResearch
PNC-27
Experimental anti-cancer peptide
Typical dose
~1–2 mg
per protocol · SubQ · highly experimental
Half-life
short
What is PNC-27?
Membrane-disrupting peptide studied in cancer research; highly experimental.
How PNC-27 works
A peptide designed to bind HDM-2 on cancer-cell membranes, forming pores that selectively lyse cancer cells while sparing normal cells (in vitro/animal models).
Benefits & uses
- Selectively kills cancer cells in lab studies (membrane disruption)
- Cancer-research interest
Common uses: Anti-cancer research (experimental — NOT a treatment).
PNC-27 dosage
- Typical dose
- Highly experimental research peptide; dosing varies (~1–2 mg SubQ). Minimal human data.
PNC-27 half-life
short
PNC-27 side effects
- No established human safety profile
- Unknown human side effects
Warnings & monitoring
- 🔴 Experimental anti-cancer research peptide — NO human clinical validation as a treatment. This is NOT a cancer therapy. Anyone with cancer must work with an oncologist. Research/informational only.
Preparation & storage
- Preparation
- Mix a 10 mg vial with 2 mL bac water → 5 mg/mL. A 2 mg dose = 0.4 mL = 40 units.
- Reconstitution
- Reconstitute a 10 mg vial with 2 mL BAC water → 5 mg/mL. A 2 mg dose = 0.4 mL = 40 units on a U-100 syringe.
Track PNC-27 in Protokol.
Log doses, model half-lives, check interactions, and line it all up against your bloodwork. Free on iPhone and Android.
